.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,856,346

« Back to Dashboard
Patent 5,856,346 protects CLEVIPREX and is included in one NDA.

This patent has forty patent family members in thirty countries.

Summary for Patent: 5,856,346

Title: Short-acting dihydropyridines
Abstract:Compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano, trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from straight or branched lower (1-5 carbon atoms) alkyl groups, and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert.-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/2'-trifluormethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.1 /R.sub.2 is hydrogen/3'-nitro, then R.sub.4 are not methyl, ethyl, propyl, iso-propyl, tert.-butyl, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in lowering the blood pressure.
Inventor(s): Andersson; Kjell Hjalmar (Fjar.ang.s, SE), Nordlander; Margareta (Askim, SE), Westerlund; Rolf Christer (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/356,224
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Chiesi Usa Inc
CLEVIPREX
clevidipine
EMULSION;INTRAVENOUS022156-001Aug 1, 2008RXYes5,856,346► subscribeYY CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
Chiesi Usa Inc
CLEVIPREX
clevidipine
EMULSION;INTRAVENOUS022156-002Aug 1, 2008RXYes5,856,346► subscribeYY CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
Chiesi Usa Inc
CLEVIPREX
clevidipine
EMULSION;INTRAVENOUS022156-003Nov 8, 2013RXYes5,856,346► subscribeYY CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,856,346

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9303657Nov 05, 1993
PCT Information
PCT FiledNovember 03, 1994PCT Application Number:PCT/SE94/01031
PCT Publication Date:May 11, 1995PCT Publication Number: WO95/12578

International Patent Family for Patent: 5,856,346

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria194330► subscribe
Australia685532► subscribe
Australia8119694► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc